Asthma: acute exacerbation: regular ipratropium and fenoterol improved lung function better than fenoterol alone.
|
|
|
Clinical bottom line (level 1b)
-
Patients admitted to hospital with acute asthma who received ipratropium and fenoterol compared with fenoterol alone had a greater improvement in FEV1 at 48 hours.
|
|
Bryant
:
Chest
1985;
88 (1):
24-29
|
Expires
November 2002
|
The study
Double-blinded concealed randomised
trial
with
intention-to-treat
Setting: thoracic unit, university hospital, Australia
28 patients
(aged
mean 40 years,
54%
male)
admitted with acute asthma
Excluded if
PEFR > 75% predicted
severe asthma; PEFR < 25% predicted, pO2 < 60 mmHg, pCO2 > 45 mmHg
history of cigarette smoking
Control Group: (n = 13, 13 analysed):
placebo
Experimental Group: (n = 15, 15 analysed):
500 mcg
ipratropium
nebulised every six hours
All patients received fenoterol 1mg nebulised every six hours. No patients received steroids during the study.
100% followed for
3
months
The evidence
| Outcome |
Control Group (SD) |
Experimental Group (SD) |
Mean Difference (95% CI) |
| mean change in FEV1 at 48 hours (l/min)
|
40.1
(7.2)
|
54.3
(9.2)
|
14
(7.7 to 21)
|
There was no significant difference in side effects noted between the two groups.
Comments
- It is unclear whether nebulised ipratropium and short acting beta2-agonist is better than more frequent use of short acting beta2-agonist or not as an immediate treatment.
- No comments were made on long-term consequences of using ipratropium.
- We would like to know if there is a difference of effect between delivery device ( MDI with spacer or wet nebulization )
Citation
-
Bryant
DH,
:
nebulized ipratropium bromide in the treatment of acute asthma.
Chest
1985;
88 (1):
24-29
Search Terms:
acute asthma in Cochrane
Contributor: Chris Ball and Clare Wotton,
November 2000
Reviewer: Mitsuhiro Kamei
Clinical Question.
| Patient |
acute asthma |
| Intervention or Exposure |
ipratropium and fenoterol |
| Comparison |
fenoterol alone |
| Outcome |
peak flow |
|
|